Search Results
Your search for ,aGe matches 8736 pages
Showing 2551 - 2600Actionable Mutations Identified in Majority of Genome-Sequenced Resected Cholangiocarcinomas
Tumor genomic profiling of resected cholangiocarcinomas may reveal mutations targetable with agents currently being used for other cancers, according to the results of a study presented at the Society of Surgical Oncology (SSO) 2021 International Conference on Surgical Cancer Care.1 Among patients...
Association of Community Cancer Centers Releases Report: Trending Now in Cancer Care 2020
The Association of Community Cancer Centers (ACCC) released Trending Now in Cancer Care 2020, an annual report that identifies current and emerging trends in cancer programs across the country. The detailed report presents findings from focus groups that illuminate the short- and long-term impact...
Cancer Has Taught Me to Live With Purpose
I have had two life-threatening cancers over the past 3 decades and can say without equivocation that there is never a good time to get cancer. My first cancer diagnosis happened in 1992, just weeks after I had accepted the position of Chief Executive Officer of Hughes Electronics. The job meant a...
Coagulopathy and COVID-19 Infection
“Life is short, art long, opportunity fleeting, experience treacherous, judgment difficult.” —Hippocrates To complement The ASCO Post’s continued comprehensive coverage of the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the...
Improving Prediction of Risk for 10-Year Left-Ventricular Systolic Dysfunction in Survivors of Childhood Cancer
In a Dutch study reported in JACC: CardioOncology, Jan M. Leerink, PhD candidate, of Amsterdam UMC, University of Amsterdam Department of Clinical and Experimental Cardiology, and colleagues found that the addition of ejection fraction measurement at the time of first surveillance echocardiogram...
First-Line Nivolumab Plus Cabozantinib Improves Progression-Free and Overall Survival vs Sunitinib in Advanced Renal Cell Carcinoma
As reported in The New England Journal of Medicine by Toni K. Choueiri, MD, of Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, and colleagues, the phase III CheckMate 9ER trial has shown that the combination of nivolumab and cabozantinib improved progression-free survival and...
ASCO Honors 2021 Special Awards Recipients
Researchers, patient advocates, and global oncology leaders who have worked to reshape cancer care around the world are among the recipients of ASCO’s Special Awards—the Society’s highest honors—and the Women Who Conquer Cancer Mentorship Awards from Conquer Cancer, the ASCO Foundation. “The...
Cognitive Performance at Baseline and Over Time in Infants Treated for Brain Tumors
In a prospective longitudinal trial reported in the Journal of Clinical Oncology, Ali et al found that infants treated for central nervous system (CNS) malignancies had baseline intellectual quotient (IQ) and parent-reported working memory and adaptive functioning worse than normative expectations; ...
Machine Learning–Based Algorithm May Predict Short-Term Mortality in Patients With Cancer and Prompt Serious Illness Conversations
Although most patients with terminal cancer, 87%, have end-of-life conversations with clinicians about their goals and preferences for care, on average, these discussions happen just 1 month before death and most often occur in acute care settings with clinicians who are not their treating...
Oral Azacitidine Improves Overall Survival vs Placebo as Maintenance Therapy for AML in First Remission
As reported in The New England Journal of Medicine by Andrew H. Wei, MB, BS, PhD, of the Australian Centre for Blood Diseases, Monash University, Melbourne, and colleagues, the phase III QUAZAR AML-001 trial has shown prolonged overall survival with oral azacitidine maintenance therapy vs placebo...
2021 Genitourinary Cancers Symposium: Advancements in the Care of Older Adults With Prostate Cancer
The 2021 Genitourinary (GU) Cancers Symposium was held in a virtual format on February 11–13 and featured the latest developments in the understanding and treatment of genitourinary cancers. The impact of prostate cancer therapies on outcomes in older adults continues to be a growing area of...
NCCN Clinical Practice Guidelines in Oncology: 2021 Updates
In 1996, the National Comprehensive Cancer Network® (NCCN®) published its first set of Clinical Practice Guidelines in Oncology®, covering eight tumor types. Guidelines are now published for more than 60 tumor types and topics. During the NCCN’s 26th Annual Conference, which was held virtually...
Selpercatinib Makes Inroads in Other RET Fusion–Positive Tumor Types
The selective RET inhibitor selpercatinib is now approved for RET fusion–positive lung and thyroid cancers. New evidence presented at the virtual edition of the American Association for Cancer Research (AACR) Annual Meeting 2021 shows that selpercatinib is active against other RET fusion–positive...
Reduced-Intensity Oxaliplatin/Capecitabine for Older and Frail Patients With Advanced Gastroesophageal Cancer
In the phase III GO2 trial reported in JAMA Oncology, Hall et al found that reduced-intensity oxaliplatin/capecitabine was associated with improved patient experience, reduced toxicity, and noninferior progression-free survival compared with higher-intensity treatment among older and frail patients ...
Frailty Can Be a Serious Issue in Ovarian Cancer
Frailty is a better predictor than age of poor outcomes in patients with ovarian cancer, according to studies reported at the Society of Gynecologic Oncology (SGO) 2021 Virtual Annual Meeting on Women’s Cancer. Researchers found that frail patients are less likely to undergo surgery, have more...
American Cancer Society Releases Report on Cancer Prevention and Screening
An American Cancer Society (ACS) review of cancer prevention and early detection measures for 2018 and 2019 in the United States shows mixed progress. Smoking prevalence during this time was at an historic low, partly because most people who ever smoked have quit. However, obesity rates remained...
Standard Multigene Testing Could Detect More Hereditary Cancer Syndromes in Patients With Colorectal Cancer
Up to 38.6% of people with colon cancer who have a hereditary cancer syndrome—including 6.3% of those with Lynch syndrome—could have their conditions remain undetected with current universal tumor-screening methods, and at least 7.1% of people with colorectal cancer have an identifiable inherited...
Increased PSA Screening Linked to Lower Risk of Advanced Prostate Cancer at Diagnosis and Death From the Disease in Younger Black Patients
Younger Black men undergoing frequent prostate-specific antigen (PSA) screening appear to have both a lower risk of metastasis at the time of prostate cancer diagnosis and of fatal disease, according to data from an observational study by Qiao et al presented at a presscast in advance of the 2021...
Study Finds Income Eligibility Limits for Medicaid May Be Associated With Worse Long-Term Survival Among Newly Diagnosed Patients With Cancer
A study investigating the association between state Medicaid income eligibility limits and long-term survival among newly diagnosed patients with cancer has found that patients living in states with lower Medicaid income eligibility limits had worse long-term survival compared with patients living...
With the Exception of Cervical Cancer, HPV-Related Cancers Are on the Rise, Especially in Older Adults
Although the incidence of cervical cancer has decreased by 1.03% a year over the last 16 years—likely due to screening or human papillomavirus (HPV) vaccination—other HPV-related cancers are increasing in both men and women, according to a study by Liao et al presented at a presscast in advance of...
USPSTF Issues New Recommendation Statement on Colorectal Cancer Screening
Prompted by a rise in cases of colorectal cancer in people younger than 50, the U.S. Preventive Services Task Force (USPSTF) has recommended that individuals at average risk for the disease begin screening exams at age 45 instead of the traditional age of 50. The guideline changes, published in...
Single-Agent Pembrolizumab Yields High Response Rates in Patients With Cutaneous Squamous Cell Carcinoma
Single-agent pembrolizumab achieved durable responses and promising survival in patients with locally advanced or recurrent/metastatic cutaneous squamous cell carcinoma, according to the second interim analysis of the phase II KEYNOTE-629 study, which was presented at the virtual American...
Risk of Second Cancer by Hormone Receptor Status Among Breast Cancer Survivors
A new study has found breast cancer survivors in general have higher risk of new cancer diagnosis compared to healthy individuals. The article, published by Hyuna Sung, PhD, and colleagues in the journal Cancer, stated that compared to the general population in the United States, the risk of new...
Longitudinal Evaluation of Functioning in Children With Retinoblastoma
In a single-institution study reported in the Journal of Clinical Oncology, Willard et al found that improvements in cognitive and adaptive function were observed between ages 5 and 10 years in many children with retinoblastoma, with scores by age 10 generally being within normal limits. Poorer...
Dual BRAF/MEK Inhibition Under Study in BRAF V600E–Mutant Gliomas
The combination of dabrafenib plus trametinib led to encouraging and durable responses in patients with low- and high-grade gliomas harboring BRAF V600E mutations, according to the results of the phase II basket study known as ROAR. Results were presented during the virtual edition of the American...
Frail Patients With Newly Diagnosed Multiple Myeloma: Triplet Regimen
In the phase II Hovon 143 trial reported in the Journal of Clinical Oncology, Stege et al found that a regimen of ixazomib, daratumumab, and low-dose dexamethasone (Ixa-Dara-dex) was associated with a high response rate in frail patients with newly diagnosed multiple myeloma, but also a high rate...
Disparities in Enrollment Into Electronic Health Record Patient Portals for Oncology Patients
In a single-institution retrospective study reported in a research letter in JAMA Oncology, Sinha et al found disparities in electronic health record (EHR) patient portal enrollment according to age, sex, race/ethnicity, and primary language among oncology patients. Study Details The study involved ...
Effect of Publication of the LACC Trial on Use of Minimally Invasive Surgery for Cervical Cancer
The Laparoscopic Approach to Cervical Cancer (LACC) trial, reported in November 2018, showed poorer disease-free and overall survival with minimally invasive vs open radical hysterectomy for early-stage cervical cancer. In a study recently reported in a letter in The New England Journal of...
Long-Term Follow-up of Premenopausal Patients With Estrogen Receptor–Positive Breast Cancer: Goserelin and Tamoxifen
A 20-year follow-up of premenopausal patients with estrogen receptor–positive breast cancer and stratification by the molecular 70-gene risk signature suggested that patients at high risk of distant disease recurrence derive significant benefit from goserelin, while patients at low risk have...
ACMG Clinical Practice Resource Provides New Guidance for Management of Individuals With PALB2 Gene Variants
The American College of Medical Genetics and Genomics (ACMG) has released a clinical practice resource from a global team of specialists in cancer genetics that will help inform the clinical management of patients who harbor a PALB2 variant and may be at increased risk of developing breast,...
Stage IV PD-L1–High Non–Small Cell Lung Cancer: Immunotherapy Alone or With Chemotherapy?
Except in patients with no smoking history, the addition of chemotherapy to immunotherapy does not add benefit as a first-line treatment in patients with stage IV nonsquamous non–small cell lung cancer (NSCLC) and high expression of PD-L1, according to real-world experience. Outcomes from the U.S. ...
Surveillance Protocol and Early Cancer Detection in Patients With Constitutional Mismatch Repair Deficiency Syndrome
As reported in the Journal of Clinical Oncology by Durno et al in the International Replication Repair Deficiency Consortium (IRRDC), use of an IRRDC surveillance protocol was associated with improved overall survival among patients with constitutional mismatch repair deficiency syndrome (CMMRD)....
FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine for Emergency Use in Adolescents
On May 10, the U.S. Food and Drug Administration (FDA) expanded the emergency use authorization (EUA) for the Pfizer-BioNTech COVID-19 vaccine for the prevention of COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to include adolescents aged 12 through 15. The FDA...
Margetuximab-cmkb: A Novel Agent Overshadowed by an Abundance of Options in HER2-Positive Breast Cancer
It is incredible to reflect upon the scientific advances in the treatment of HER2-positive breast cancer over the past 23 years. Once considered the worst subtype of breast cancer, HER2-positive disease is now associated with the best long-term outcomes in this age of targeted treatments. With a...
Margetuximab-cmkb Plus Chemotherapy Prolongs Progression-Free Survival in Heavily Pretreated HER2-Positive Breast Cancer
As reported in JAMA Oncology by Hope S. Rugo, MD, of the University of California San Francisco Helen Diller Family Comprehensive Cancer Center, and colleagues, the phase III SOPHIA trial has shown significantly prolonged progression-free survival with margetuximab-cmkb plus chemotherapy vs...
Study Finds Adjuvant Immunotherapy of Benefit to Patients With Stage IIB/C Melanoma
A significant survival advantage accrued to patients with stage IIB and IIC cutaneous melanoma who received adjuvant immunotherapy, a large retrospective cohort study reported at the Society of Surgical Oncology (SSO) 2021 International Conference on Surgical Cancer Care.1 The 3-year overall...
Comparing Nivolumab Plus Ipilimumab vs Nivolumab Alone in Resected Stage III to IV Melanoma
The addition of ipilimumab to nivolumab failed to improve outcomes compared with nivolumab alone as adjuvant therapy for resected melanoma, according to the results of the CheckMate 915 trial, presented at the virtual edition of the American Association for Cancer Research (AACR) Annual Meeting...
CHRONOS-3: Addition of Copanlisib to Rituximab Extends Progression-Free Survival in Relapsed Indolent NHL
The combination of the PI3K inhibitor copanlisib plus the monoclonal antibody rituximab reduced the risk of disease progression or death by 48% compared with placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (NHL), according to the results of the phase III CHRONOS-3...
Bispecific Antibody Platform: Early Data in Relapsed and Refractory Myeloma
“There was never a night or a problem that could defeat sunrise or hope.” —Bernard Williams To complement The ASCO Post’s continued comprehensive coverage of the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting...
Tebentafusp Shows Overall Survival Benefit in First-Line Treatment of Metastatic Uveal Melanoma
Treatment with tebentafusp—a novel bispecific fusion protein—reduced the risk of death from metastatic uveal melanoma by half, compared with available treatments, in a phase III study presented at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021.1 This is the first...
Shared Risk Factors for Preventing Cancer and Cardiovascular Disease: The Evolving Focus of Cardio-oncology
Cardio-oncology represents the intersection of cancer and cardiovascular disease. Cancer therapies can result in cardiovascular complications, and some patients become less attentive to their chronic disease management after a diagnosis of cancer. As cancer patients are living longer, for some,...
Are Prevalent Cardiovascular Risk Factors Associated With Increased Risk of Subsequent Cancer?
In a study reported in JACC: CardioOncology, Emily S. Lau, MD, of the Cardiology Division, Department of Medicine, Massachusetts General Hospital, and colleagues found that the presence of cardiovascular disease (CVD) risk factors was significantly associated with an increased risk of future...
Phase II Trial Reports Anticancer Activity With Novel FGFR Inhibitor in Advanced Intrahepatic Cholangiocarcinoma
Futibatinib—a selective, fibroblast growth factor receptor (FGFR) inhibitor—demonstrated anticancer activity in patients with advanced intrahepatic cholangiocarcinoma and FGFR2 fusions or rearrangements. These findings are based on the primary results of the phase II FOENIX-CCA2 trial, which were...
Relationship Between Germline BRCA Pathogenic Variants and Diminished Ovarian Reserve
In a study reported in the Journal of Clinical Oncology, Turan et al found the presence of germline BRCA pathogenic variants was associated with diminished ovarian reserve in young women, particularly in those diagnosed with breast cancer and those with BRCA1 variants. Study Details The individual...
Accuracy of Lung Cancer Risk Model in Diverse Populations
A commonly used risk prediction model does not accurately identify high-risk Black patients with lung cancer who could gain life-saving benefit from early screening—paving the way for improving screenings and guidelines. These findings were published in a research letter by Shusted et al in JAMA...
Risk of Colorectal Cancer and Colorectal Polyps in First-Degree Family Members
Researchers have demonstrated a possible connection between colorectal polyps in close relatives and the risk of developing colorectal cancer. The study, which was published by Song et al in the British Medical Journal, is of potential consequence for cancer screening procedures. Colorectal cancer...
Antiviral T Cells for BK Virus–Associated Hemorrhagic Cystitis
A phase II trial has found found that BK virus (BKV)-specific T cells from healthy donors were safe and effective as an off-the-shelf therapy for BKV-associated hemorrhagic cystitis, a painful complication that is common after allogeneic stem cell transplants for patients with leukemia or lymphoma. ...
First-Line Immune Checkpoint Inhibitor Monotherapy vs Chemoimmunotherapy in Advanced NSCLC According to KRAS Variant Status
In a study reported in a research letter in JAMA Oncology, Sun et al found that first-line immune checkpoint inhibitor monotherapy was associated with better overall survival among patients with advanced non–small cell lung cancer (NSCLC) with PD-L1 expression ≥ 50% and KRAS variant vs KRAS...
First-Line Single-Agent Carboplatin vs Carboplatin/Paclitaxel in Older Women With Ovarian Cancer
In a phase II trial reported in JAMA Oncology, Falandry et al found that single-agent carboplatin was associated with poorer survival vs a standard carboplatin/paclitaxel regimen as first-line treatment for stage III/IV ovarian cancer in women aged 70 or older with high geriatric vulnerability...
Factors Associated With Unplanned Hospitalizations Among Older Patients Receiving Chemotherapy
In a study reported in JCO Oncology Practice, Klepin et al identified several factors associated with unplanned hospitalizations and hospital length of stay among patients with cancer aged 65 and older receiving chemotherapy. Study Details The study was a secondary analysis in a U.S. multisite...
